Can you take Vyvanse on an empty stomach?
By
Dr Drielli Vital-Fujii (PhD)
Author bio
Dr Drielli Vital-Fujii, PhD, is a Pharmacist with expertise in Drug Design and Development, Enzymes, Molecular Modelling, and Photodynamic Therapy. She writes and reviews content on these topics.
Dr Drielli Vital-Fujii’s Highlights:
- Postdoctoral fellow at the Department of Biochemistry at the University of São Paulo, emphasizing therapy of neglected diseases using light.
- PhD in Pharmaceutical Sciences focusing on drug design and development at the Faculty of Pharmaceutical Sciences of the University of São Paulo.
- Six months as an international researcher at the Center for Discovery and Innovation in Parasitic Diseases (University of California San Diego)
- Master’s degree in Pharmaceutical Sciences focusing on drug design and development at the Faculty of Pharmaceutical Sciences of the University of São Paulo.
- Bachelor of Pharmacy at the University of Mogi das Cruzes – São Paulo / Brazil
Professional Experience:
2012 – 2018 Project manager at University of São Paulo – Pharmacy Department
Dr Drielli Vital-Fujii has worked with computational studies, synthesis, biological evaluation, design, and development of new inhibitor candidates for Chagas Disease and Leishmaniasis.
2017 – 2017 International research fellow at University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences – Center for Discovery and Innovation in Parasitic Diseases.
She used Virtual Screening (VS) and High-Throughput Screening (HTS) Integration in the Discovery of new drugs against neglected tropical diseases (NTDs).
2018 – 2019 Faculdades Oswaldo Cruz
Dr Drielli Vital-Fujii was a professor in the Faculty of Pharmacy, teaching the subjects of Pharmaceutical Chemistry and Drug Development.
2019 – 2021 Researcher in Biochemistry University of São Paulo – Biochemistry Department
She applied Photodynamic Therapy in Leishmaniasis Treatment, mentored undergraduate students in scientific activities, and wrote, executed, translated, and reported scientific projects with funding agencies.
2023-2023 UniPiaget – University Center.
Dr Drielli Vital-Fujii was a Biology, Nutrition, Physiotherapy, and Pharmacy professor.
Education:
2018 -2021 Postdoctoral at the Department of Biochemistry at the University of São Paulo
2013 -2018 PhD of Science: Drugs and Medicines at Department of Pharmacy at University of São Paulo
2012 -2013 M.Sc. of Sciences: Drugs and Medicines at the Department of Pharmacy at the University of São Paulo
2005-2008 Bachelor of Pharmacy at the University of Mogi das Cruzes
The leading publications of Dr Drielli Vital-Fujii are:
Vital-Fujii, D.G, Baptista, M.S. (2021). Progress in the photodynamic therapy treatment of Leishmaniasis. Brazilian Journal of Medical and Biological Research, 54, 1-11.
Gatti, F. M., Gomes, R.A., da Fonseca, A.L., Lima, E.J.C., Vital-Fujii, D.G., Taranto, A.G., Varotti, F.P., Trossini, G.H.G. (2020). Antiplasmodial activity of sulfonylhydrazones: in vitro and in silico approaches. Future medicinal chemistry, 13, 233-250.
Silva, E.J., Bezerra-Souza, A., Passero, L.F., Laurenti, M.D., Ferreira, G.M., Fujii, D.G.V., et al. (2018). Synthesis, leishmanicidal activity, structural descriptors and structure-activity relationship of quinoline derivatives. Future medicinal chemistry, 10, 2069-2085.
Leite, F.H.A., Froes, T.Q., da Silva, S.G., de Souza, E.I.M., Vital-Fuji,i D.G., Trossini, G.H.G., et al. (2017). An integrated approach towards the discovery of novel non-nucleoside Leishmania major pteridine reductase 1 inhibitors. European Journal of Medicinal Chemistry, 132, 322-332.
Vital, D.G., Damasceno, F.S., Rapado, L.N., Silber, A.M., Vilella, F.S., Ferreira, R.S., et al. (2017). Application of bioisosterism in design of the semicarbazone derivatives as cruzain inhibitors: a theoretical and experimental study. Journal of Biomolecular Structure and Dynamics, 35, 1244–1259.
Mello, J. F.R., Gomes, R.A., Vital-Fujii, D.G., Ferreira, G.M., Trossini, G.H.G. (2017). Fragment-based drug discovery as alternative strategy to the drug development for neglected diseases. Chemical Biology & Drug Design, 90, 1067-1078.
Pantaleao, S.Q., Fujii, D.G.V., Maltarollo, V.G., da C. Silva, D., Trossini, G.H.G., Weber, K.C., et al. (2017). The Role of QSAR and Virtual Screening Studies in Type 2 Diabetes Drug Discovery. Medicinal Chemistry, 13, 706-720.
Vital, D., Arribas, M., Trossini, G. (2014). Molecular Modeling and Docking Application to Evaluate Cruzain Inhibitory Activity by Chalcones and Hydrazides. Letters in Drug Design and Discovery, 11, 249-255.
Blau, L., Menegon, R.F., Trossini, G.H.G., Molino, J.V.D., Vital, D.G., Cicarelli, R.M.B., et al. (2013). Design, synthesis and biological evaluation of new aryl thiosemicarbazone as antichagasic candidates. European Journal of Medicinal Chemistry, 67, 142-151.
You can view some of Dr Drielli’s work below and links to her professional profile.
Orcid: https://orcid.org/0000-0001-9270-0466
Research Gate: https://www.researchgate.net/profile/Drielli-Gomes-Vital-Fujii
Scopus: https://www.scopus.com/authid/detail.uri?authorId=55829534000
Google Scholar: https://scholar.google.com/citations?user=F9U50AEAAAAJ&hl=pt-BR
Linkedin: linkedin.com/in/driellivital
Escavador: https://www.escavador.com/sobre/6101380/drielli-gomes-vital
CDIPD: https://cdipd.org/index.php/about-us/visiting-scientists
Can you take Vyvanse on an empty stomach?
Yes, you can take Vyvanse on an empty stomach. The medication can be taken with or without food and it doesn’t come with any dietary restrictions. (1)
Taking Vyvanse on an empty stomach can have both potential benefits and risks, which are important to consider before deciding when and how to take the medication. It’s crucial to follow the dosing instructions provided by your healthcare provider and discuss any concerns or questions with them.
Potential benefits of taking Vyvanse on an empty stomach
Taking Vyvanse on an empty stomach can have some potential benefits. These include:
Enhanced Absorption
Taking Vyvanse on an empty stomach may lead to enhanced absorption of the medication into the bloodstream. When the stomach is empty, there is less food present that could potentially interfere with the absorption process.
This can result in a quicker onset of action and more consistent blood levels of the medication.
Faster Effects
By taking Vyvanse on an empty stomach, the medication may start working more quickly. The absence of food in the stomach allows the medication to be absorbed and enter the bloodstream faster, leading to a more rapid onset of therapeutic effects. (2,3)
This can be particularly beneficial for individuals who require immediate symptom relief or need the medication to be effective during specific times of the day.
Increased Concentration
When Vyvanse is taken on an empty stomach, the concentration of the medication in the bloodstream may be higher compared to taking it with food.
This can result in a potentially stronger therapeutic effect, especially for individuals who require higher doses to achieve the desired response. However, it’s important to note that dosage adjustments should only be made under the guidance of a healthcare professional.
Potential risks of taking Vyvanse on an empty stomach
Taking Vyvanse on an empty stomach can have some potential risks. These include:
Gastrointestinal Discomfort
Taking Vyvanse on an empty stomach can increase the risk of experiencing gastrointestinal discomforts, such as nausea, stomach pain, or acid reflux. (3)
The absence of food in the stomach may irritate the stomach lining and lead to these unwanted side effects. If you are prone to stomach issues or have a sensitive digestive system, taking Vyvanse with a small meal or snack may help mitigate these risks.
It is also important to make sure that you do not split Vyvanse tablets in half, as these tablets are entended-release and cutting them can cause the drug to release rapidly, causing more severe side effects.
Appetite Suppression
Vyvanse is known to suppress appetite, and taking it on an empty stomach can amplify this effect. For individuals who struggle with maintaining a healthy appetite or have difficulty meeting their nutritional needs, taking Vyvanse on an empty stomach may further reduce their desire to eat.
This can potentially lead to inadequate calorie intake and nutritional deficiencies over time. It’s important to ensure proper nutrition and discuss any concerns with a healthcare provider.
Other side effects
While taking Vyvanse on an empty stomach may lead to faster effects and enhanced concentration, it may also increase the likelihood of experiencing certain side effects.
Common side effects of Vyvanse include headache, dry mouth, insomnia, and nervousness (3). Taking the medication on an empty stomach may intensify these side effects, particularly in individuals who are more sensitive to stimulant medications.
Final words
To sum up, taking Vyvanse on an empty stomach can have potential benefits such as enhanced absorption, faster effects, and increased concentration. However, it also carries risks including gastrointestinal discomfort, appetite suppression, and an increased potential for side effects.
It’s important to weigh these factors and consider individual circumstances when deciding whether to take Vyvanse on an empty stomach. Consulting with a healthcare professional is advised to determine the most appropriate dosing regimen for your specific needs.
Was this helpful?
References
1.-
HIGHLIGHTS OF PRESCRIBING INFORMATION. United States Food and Drug Administration (FDA). VYVANSE ® (lisdexamfetamine dimesylate) capsules, for oral use, CII VYVANSE ® (lisdexamfetamine dimesylate) chewable tablets, for oral use, CII. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208510lbl.pdf
2.-
VyvanseTM (lisdexamfetamine dimesylate). Full drug information”. United States Food and Drug Administration (FDA). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021977lbl.pdf
3.-
Goodman DW. Lisdexamfetamine dimesylate (Vyvanse), a prodrug stimulant for attention-deficit/hyperactivity disorder. P T. 2010 May;35(5):273-87. PMID: 20514273; PMCID: PMC2873712. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2873712/ Goodman DW. Lisdexamfetamine dimesylate (Vyvanse), a prodrug stimulant for attention-deficit/hyperactivity disorder. P T. 2010 May;35(5):273-87. PMID: 20514273; PMCID: PMC2873712. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2873712/
